Aurora Cannabis Reports Record-Breaking Q3 2025 Financial Results

LOS ANGELES- Aurora Cannabis Inc. announced its fiscal third-quarter 2025 results, highlighting significant growth in revenue and profitability.

Financial Highlights:

• Net Revenue: The company reported net revenue of C$88.2 million for the quarter ending December 31, 2024, marking a 37% increase from C$64.4 million in the same period the previous year.
• Medical Cannabis Revenue: Medical cannabis net revenue reached C$68.1 million, a 51% rise from the prior year’s quarter, accounting for 77% of Aurora’s total net revenue.
• Adjusted Gross Margin: The adjusted gross margin before fair value adjustments improved to 65%, up from 53% in the previous year, reflecting enhanced operational efficiency.
• Adjusted EBITDA: Adjusted EBITDA increased by 316% to C$23.1 million, compared to C$5.5 million in the same quarter last year.

Segment Performance:

• Global Medical Cannabis: The 51% growth in this segment was driven by higher sales in Australia, Germany, Poland, and the UK, as well as increased revenue from insurance-covered and self-paying patients in Canada.
• Plant Propagation: The plant propagation segment saw a 22% increase in net revenue, attributed to organic expansion and an enhanced product portfolio.
• Consumer Cannabis: Net revenue in the consumer cannabis segment decreased by 15% to C$9.9 million, primarily due to the company’s strategic focus on supplying Good Manufacturing Practice (GMP) certified products to the higher-margin global medical cannabis market.

International net revenue grew by 112%, now representing 60% of Aurora’s global medical cannabis net revenue.

Miguel Martin, Executive Chairman and CEO of Aurora Cannabis, stated, “This quarter was record-breaking for Aurora, driven by all-time highs in global medical net revenue, net income, adjusted EBITDA, and free cash flow. These achievements, along with our strong cash position and debt-free cannabis business, underscore Aurora’s leadership in the global cannabis industry as we continue to set ourselves apart from our peers.”

Aurora anticipates continued revenue growth in the fourth quarter of fiscal 2025, driven by international medical cannabis sales and a seasonal increase in plant propagation revenue. The company expects to maintain strong profit margins and positive adjusted EBITDA, with improved cash flow resulting from disciplined spending and revenue growth.